Status:
COMPLETED
Perceptions of Cell and Gene Therapies (CGT) for the Treatment of Cancer
Lead Sponsor:
GlaxoSmithKline
Conditions:
Neoplasms
Eligibility:
All Genders
18+ years
Brief Summary
Gene and cell therapies have a real value potential (example: potential long-term effect, curative potential, and single administration) but also drawbacks (example: treatment perceived as complex and...
Eligibility Criteria
Inclusion
- For cancer subjects:
- Adults 18 years of age and older of any, sex, racial/ethnic group, or economic status
- With a self-reported diagnosis of non-small-cell lung carcinoma (NSCLC), soft tissue sarcomas, or hematological malignancies
- Willing and able to participate in a telephone interview
- Willing to be audio-recorded during the interview session
- For Oncologists:
- Education credentials equivalent to Doctor of Medicine (MD)
- Oncologist/hematologist-oncologist with at least five years of experience in oncology
- Able to fluently read, speak, and understand English to participate in an interview and/or complete all assessments
- Willing and able to participate in a telephone interview
- Willing to be audio-recorded during the interview session
Exclusion
- For cancer subjects:
- Diagnosed with cancer less than a year ago or those on first line of treatment at the time of the interview
- Unable to provide information on their line of treatment
- Significant speech impairment, cognitive impairment, hearing difficulty, visual impairment, or severe psychopathology (according to the opinion of the screener)
- Any clinically-relevant medical condition including, but not limited to, severe co-morbid condition, severe mental illness, substance abuse, cognitive, or other impairment (e.g., visual) which, in the opinion of the investigator, would interfere with participating in an interview and/or completing the study procedures.
- For Oncologists:
- Currently unable to practice medicine and/or treat subjects, for reasons including (but not limited to): expired medical license, revoked medical license, or part of the Food and Drug Administration (FDA) debarment list.
Key Trial Info
Start Date :
December 4 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 12 2018
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03336567
Start Date
December 4 2017
End Date
June 12 2018
Last Update
February 5 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Collegeville, Pennsylvania, United States, 19426